Canadian Drug and Substance Watch: Highlights

The Canadian Drug and Substance Watch (CDSW) is a drug early warning system designed to highlight new and emerging substances on the illegal drug market.

  • Last updated: 2026-03-09

The Canadian Drug and Substance Watch (CDSW) combines data from multiple sources, such as:

The CDSW builds on surveillance activities that monitor drugs in Canada. It better informs government organizations, public health officials, law enforcement and border control agencies to develop public health responses in addressing the crisis. These responses prevent the spread of emerging drugs and reduce related harms. The CDSW differs from drug alert systems, which aim to prevent immediate harm by sharing information about the precise location and appearance of drugs.

The CDSW focuses on psychoactive substances. These are drugs that affect mental processes like perception, consciousness or mood. Substances with similar effects are grouped into the same pharmacological class.

General summary

An overview of data collected by Health Canada from January 2023 to June 2025. A total of {{}} identifications were made across the data sources amounting to {{}} new and emerging unique substances. Below is a summary of the substances identified in each data source. Substances can be identified in multiple data sources.


{{}}

new and emerging substances detected in DAS samples

{{}}

new and emerging substances detected in wastewater

{{}}

new and emerging substances detected in web monitoring

Spotlight on new and emerging opioids of public health concern

Opioids, such as fentanyl, fentanyl analogues, and nitazenes are major contributors to opioid-related harms in Canada. The majority of accidental apparent opioid toxicity deaths in Canada continue to involve fentanylFootnote 1, while the proportion of these deaths involving fentanyl analogues also continues to rise. The table below displays fentanyl analogues, fentanyl precursors, and nitazenes, found in each location and data source.

Group Substance Location Data source

Interactive visualizations of new and emerging psychoactive substances

Below are interactive graphs and a map to show new and emerging psychoactive substances by province/territory and/or pharmacological class. Select a province or territory from the dropdown menu and/or a pharmacological class from the list on the left to update the results.

Province or territory

Pharmacological class

Timeframe

Number of identifications of new and emerging substances by pharmacological class and data source

This graph shows the {{}} identifications across data sources, representing {{}} unique substances. Substances identified in more than one data source are counted once per source.

Number of identifications of new and emerging substances by month and data source

This graph shows the {{}} identifications in various data sources. The same substance can be counted multiple times across the data sources and reporting month.

Number of new and emerging substances by pharmacological class

This figure displays the {{}} unique substances across data sources.

Number of new and emerging substances by pharmacological class: Text description
Location Pharmacological class Number of unique substances

To explore trends in substance appearance over time and by geography, refer to the New and emerging substances tab.

Map of identifications of new and emerging substances by pharmacological class in Canada

This map displays the number of identifications of unique substances in each province and territory. The same substance may be identified in multiple provinces or territories and in multiple data sources within each region. Each substance is counted once in each region and data source where it appears.

Interactive visualizations: Notes
  • “Canada and online” includes identifications for substances found in Canada through DAS samples and wastewater, and online from web monitoring, which is not geographically specific.
  • Wastewater counts and trends may be influenced by the number of wastewater collection sites reporting in a given time period.
  • For more information about each key pharmacological class: Understanding the data

Contact us

For comments or questions regarding data, contact Health Canada at odrs-brsd@hc-sc.gc.ca.

References

Reference 1

Substance-related Overdose and Mortality Surveillance Task Group on behalf of the Council of Chief Medical Officers of Health. Opioid- and Stimulant-related Harms in Canada. Ottawa: Public Health Agency of Canada; December 2025.

Return to reference 1 referrer

You might also be interested in

National Wastewater Drug Surveillance

Health Canada's interactive dashboard exploring the presence of drugs, their byproducts (metabolites), and related precursor chemicals based on the collection of samples from wastewater sites located across Canada.

Drug Analysis Service and Cannabis Laboratories

Health Canada's Drug Analysis Service and Cannabis Laboratory operates laboratories across Canada that analyze drugs and substances submitted by Canadian law enforcement and public health officials.

All Health Infobase data products

Did you find what you were looking for?

What was wrong?

(Don't include any personal information. Note that you will not receive a reply.)
Maximum 300 characters

Thank you for your feedback

Date modified: